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Abstract
AIM
To compare different antibiotics for eradicating the 
carriage of Neisseria meningitidis  (N. meningitidis ), and 
to investigate heterogeneity and evidence inconsistency. 
METHODS
From a search of PubMed and published systematic 
reviews, we identified 23 trials evaluating 15 antibiotics 
that could be connected in a trial network. The outcome 
of interest is the eradication of N. meningitidis . We used 
WinBUGS to conduct random-effects, mixed treatment 
comparisons. Heterogeneity and evidence inconsistency 
was investigated by meta-regression modelling and 
examining characteristics of trial participants and inter-
ventions evaluated. 
RESULTS 
Rifampin, ciprofloxacin, minocycline, ceftriaxone, 
and azythromycin were statistically significantly (P  < 
0.05) more effective than placebo. The probability 
of being the best was 67.0% for a combination of 
rifampin and minocycline, 25.0% for ceftriaxone, 1.7% 
for azythromycin, and below 1% for the remaining 
regimens. Significant inconsistency between the direct 
and indirect estimates was observed for the comparison 
of rifampin and ciprofloxacin (P  < 0.01), which may be 
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caused by different types of carriers and different doses 
of ciprofloxacin. 
CONCLUSION
A range of prophylactic antibiotic regimens are effective 
for eradicating meningococcal carriages, and treatment 
choice will depend on the individual priorities of the 
patients and physicians. In clinical situations where 
complete eradication is considered to be of the utmost 
importance, a combination of rifampin and minocycline 
seems to offer the highest likelihood of success. 
Ceftriaxone as a single intramuscular injection is also 
likely to be more effective as compared with the other 
two antibiotics (ciprofloxacin or rifampin) recommended 
by the current guidelines. 
Key words: Chemoprophylaxis; Antibiotics; Nersseria 
meningitidis ; Meningococcal infection; Network meta-
analysis
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This network meta-analysis found that a range 
of prophylactic antibiotic regimens are effective for 
eradicating meningococcal carriages. A combination of 
rifampin and minocycline seems the most efficacious, 
and ceftriaxone is also likely to be more effective than 
ciprofloxacin or rifampin alone. Careful investigation of 
significant inconsistency between direct and indirect 
comparison of rifampin and ciprofloxacin found that 
it was mainly caused by different types of carriers 
(persistent or any) and the varying doses of ciprofloxacin 
in the included trials. Detailed examination of chara-
cteristics of relevant studies should be conducted for 
investigating causes of inconsistency in network meta-
analysis. 
Abdelhamid AS, Loke YK, Abubakar I, Song F. Antibiotics for 
eradicating meningococcal carriages: Network meta-analysis 
and investigation of evidence inconsistency. World J Meta-Anal 
2016; 4(4): 77-87  Available from: URL: http://www.wjgnet.
com/2308-3840/full/v4/i4/77.htm  DOI: http://dx.doi.org/10.13105/
wjma.v4.i4.77
INTRODUCTION
Neisseria meningitidis (N. meningitidis), a Gram-nega-
tive bacterium, is a normal inhabitant of the human 
pharynx. Transmission from person to person happens 
by droplets from the upper respiratory tract causing 
meningococcal disease; the severest forms of which are 
meningitis and septicaemia[1]. Meningococcal disease 
occurs usually sporadically or in small clusters all over 
the world as in the African “meningitis belt”, from 
Ethiopia to Senegal, and also in overcrowded places or 
wherever large population movements exist[2]. 
Prevalence of meningococcal carriage varies greatly, 
from 8% to 25% in random samples of healthy 
individuals, and as high as 36% to 71% in military 
recruits, and shows a massive increase in overcrowded 
places[1]. Current public health guidelines recommend 
chemoprophylaxis to be offered to close contacts of 
cases irrespective of vaccination status[3-6]. The evidence 
behind these recommendations were mainly from 
published systematic reviews[7,8]. However, there is no 
definite evidence from the available direct comparison 
trials, as to which antibiotic is more effective in pre-
venting secondary meningococcal disease cases[9]. 
With the ever increasing number of competing inter-
ventions and a shortage of direct comparison trials, 
methods for indirect comparison and network meta-
analysis have been developed to compare different 
treatment options[10-13]. Because of limited evidence 
from direct comparison trials, we conducted a network 
meta-analysis of randomised controlled trials that 
evaluated different antibiotics for eradicating carriages 
of N. meningitidis. We also reported the methodological 
experience obtained from this work for appropriately 
investigating causes of evidence inconsistencies in 
network meta-analysis. 
MATERIALS AND METHODS
Study eligibility and identification 
We included randomised controlled trials that evaluated 
effects of antimicrobial interventions for the prevention 
of meningococcal infections. Eligible studies were 
selected according to the following criteria: (1) it was a 
randomised controlled study; (2) included participants 
who exposed to patients with meningococcal disease or 
N. meningitidis carriers; (3) evaluated chemoprophylaxis 
interventions using any antibiotic regimens; and (4) 
reported data on eradication of meningococcal carriage. 
We checked references of previous systematic reviews 
and conducted additional literature search to identify 
relevant studies for this meta-analysis. Two recently 
published high quality systematic reviews (with pair-
wise meta-analysis only) were identified, in which 
the literature searches were updated or conducted in 
June 2013[7] and in December 2013[8] respectively. 
We assessed the eligibility of studies included in these 
two reviews. To identify additional eligible studies 
possibly published after theses systematic reviews, one 
reviewer (Song F) conducted a search of PubMed in 
April 2016. The PubMed search used the following key 
words: “meningococcal” or “meningitis” combined with 
“chemoprevent*” or “chemoprophyl*” or antibiotic*” or 
antimicrobial*”. In addition, the search was limited to 
“clinical trial” and published in the last 5 years. However, 
all relevant studies in the current meta-analysis could 
be identified from existing systematic reviews, and no 
new eligible studies were identified from the search of 
PubMed. Eventually, we included 23 trials[14-35], in which 
15 different antibiotics (or combinations of antibiotics) 
could be connected in a network of trials (Figure 1). 
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Data extraction
The outcome of interest in this network meta-analysis 
is failure to eradicate meningococcal carriage up to one 
week, although only the 2-wk outcome was reported in 
one trial[14]. From the included studies, two independent 
reviewers (Asmaa S Abdelhamid and Fujian Song) 
extracted the following data: Antibiotics evaluated, the 
number of carriers, the number of carriers with failed 
eradication at one week after antibiotic prophylaxis, 
study population, carrier status, reported serogroup, 
susceptibility of meningococci to antibiotics, study 
design, adequate or inadequate allocation concealment, 
and open or blinded. Disagreements between the two 
reviewers were resolved by discussion. 
Methods for mixed treatment comparison 
In contrast to within-trial direct comparisons, adjusted 
indirect comparison is a cross-trial comparison of 
different treatments, based on a common treatment 
(for example, placebo), so that the advantage of within-
trial randomisation could be partially preserved[10]. 
Mixed treatment comparison refers to a combination 
of evidence from direct comparison trials and evidence 
based on indirect comparisons[12]. The validity of indirect 
and mixed treatment comparison depends on whether 
some basic assumptions could be fulfilled. The basic 
assumptions include homogeneity assumption for 
conventional pair-wise meta-analysis, trial similarity 
assumption for adjusted indirect comparison, and con-
sistency assumption for combining direct and indirect 
evidence[36]. Among these basic assumptions, hetero-
geneity in conventional meta-analysis and inconsis-
tency between direct and indirect evidence can be 
quantitatively assessed. 
Markov chain Monte Carlo methods in WinBUGS 
(MRC Biostatistics Unit, Cambridge, United Kingdom) 
were used to conduct the random-effects, mixed treat-
ment comparisons based on consistency assumption[37]. 
The WinBUGS code for Bayesian analysis is available 
from a report by Dias et al[37,38]. We used non-informa-
tive or vague priors, and obtained results by 200000 
iterations after a burn-in of 100000. 
Investigating heterogeneity and causes of inconsistency
When different antibiotics could be compared both 
directly and indirectly, we calculated the inconsistency 
(Δ) between the direct and indirect evidence by the 
following: 
Δ = dCB - d'CB
se(Δ) = Var (dCB) + Var (d'CB)
Where dCB and d’CB are the treatment effects (e.g., 
log odds ratio) by direct and indirect comparison of 
treatment C and B; se(Δ) is the standard error of the 
estimated inconsistency; Var(dCB) and Var(d’CB) are 
estimated variances of the treatments effects. 
We used a statistical model suggested by Cooper et 
al[39] to explore treatment by covariate interactions in 
the network meta-analysis. It estimates a regression 
coefficient by assuming a single interaction term for the 
relative effects of all the treatments vs the reference 
treatment (i.e., placebo)[38]. The effects of the following 
study-level covariates were investigated: Persistent 
carriers vs any carriers, household contacts vs other 
carriers, cluster/quasi randomised controlled trials vs 
randomised trials, adequate vs inadequate sequence 
generation, and open vs blinded design. 
We also conducted narrative investigation of causes 
of inconsistency, which was focused on detailed com-
parison of rifampin and ciprofloxacin (reasons for 
this will be provided later). The assessment of clinical 
diversity and similarity among different sets of trials 
is a process of identifying possible effect modifiers, 
which was conducted by answering the following two 
questions[40]. First, we examined whether there were 
noticeable differences in study characteristics between 
different sets of trials. Then, we considered whether 
any of the observed differences in study characteristics 
between trials may have modified the relative treatment 
effects. In this study, we examined individual trials for 
effect modifiers with special attention to carriage status, 
dose of antibiotic used and length of intervention. 
There were 14 trials that compared antibiotics and 
placebo. Using data from these placebo-controlled 
trials, we produced a funnel plot to investigate risk of 
publication bias. Asymmetry of the funnel plot was 
statistically tested using Harbord’s test for small-study 
effects[41]. All statistical analyses were conducted and 
checked by the corresponding author (Fujian Song) who 
has training and experience in statistical methods. 
RESULTS 
The main characteristics of the 23 trials are presented 
in Table 1, and data used in network meta-analyses 
are shown in Table 2. There are 20 two-arm trials, 
one three-arm trial, and two four-arm trials. The 
15 antibiotics evaluated in these trials are: Placebo, 
rifampin, ciprofloxacin, minocycline, minocycline plus 
rifampin, penicillin, ampicillin, ceftriaxone, sulphadiazine, 
sulphadimidine, azythromycin, spectinomycin, cepha-
lexin, “Sch29482”, and coumermycin A1 (Figure 1). 
Carriers were mainly from household contacts 
of cases (six trials), military recruits (seven trials), 
and students or young people (six trials). Six trials 
recruited heavy or persistent carriers (defined as two 
or more sequential positive cultures before antibiotic 
prophylaxis). The test of susceptibility to antibiotics was 
done in most of the studies. The sequence generation 
was inadequate or unclear in 11 trials. Blinding was 
performed in 12 trials, and allocation concealment was 
adequate in only three trials (Table 1). 
There were five cluster randomised trials. We could 
not find empirical data on intra-cluster correlation 
coefficient (ICC) for the included cluster randomised 
trials, and therefore estimated the effective sample 
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sizes by assuming an ICC of 0.05[42]. 
Funnel plot using data from 14 placebo-controlled 
trials is shown in Figure 2. The funnel plot was not statis-
tically significantly asymmetric (P = 0.610), indicating 
no concern about risk of small-study effects. 
 
Comparison of antibiotics
The results of the network meta-analysis are shown in 
Table 3. Rifampin, ciprofloxacin, minocycline, ceftriaxone 
and azythromycin were significantly (P < 0.05) more 
effective than placebo. The probability of being the 
most efficacious was 67.0% for a combination of 
rifampin and minocycline, 25.0% for ceftriaxone, 1.7% 
for azythromycin, and less than 1% for the remaining 
antibiotics. According to evidence from the full network 
of trials, the combination of rifampin and minocycline 
was the most efficacious intervention, and ceftriaxone 
the second (Table 3). 
The covariate effects in the network meta-analysis 
are shown in Table 4. Trials with persistent carriers 
or household contacts of cases reported significantly 
greater treatment effects as compared with trials of any 
carriers or non-household contacts of cases, while the 
remaining regression coefficients were not statistically 
significant. When the effect of persistent carrier was 
incorporated into the network meta-analysis, the 
between-study variation (τ = 0.434) was much reduced 
as compared with the between-study variation without 
significant covariate adjustment (τ > 0.937). Therefore, 
type of carriers (persistent vs any) may be an effect 
modifier[39]. However, the between-study variation was 
not reduced when the effect of household contacts was 
included in the analysis (τ = 0.975). 
Inconsistencies in the network meta-analysis
There is sufficient data for both direct and indirect 
comparisons of four pairs of antibiotics (Table 5), and 
the estimated inconsistencies between the direct and 
indirect estimates are shown in Figure 3. A statistically 
significant inconsistency was observed for the com-
parison of rifampin and ciprofloxacin. The indirect 
comparison based on 21 trials found that rifampin 
was significantly better than ciprofloxacin (OR = 0.09, 
95%CI: 0.017-0.40 for failure to eradicate). In contrast, 
the pooling of two direct comparison trials suggested that 
rifampin therapy was less effective than ciprofloxacin, 
with a greater likelihood (non-statistically significant) of 
failure to eradicate (OR = 2.51, 95%CI: 0.36-15.64). 
Our further investigation of causes of inconsistency 
was therefore focused on the comparison of rifampin 
and ciprofloxacin. These are also the antibiotics recom-
mended in the current clinical guidelines. The incon-
sistency investigation was using data from two direct 
comparison trials[16,29], six placebo-controlled trials of 
rifampin[15,17,19,20,26,28] and three placebo-controlled trials 
of ciprofloxacin[24,31,33]. Figure 4 shows the results of the 
individual trials, with the overall estimates of direct and 
indirect comparisons. 
While placebo controlled trials of rifampin included 
mostly any carriers, three placebo controlled trials of 
ciprofloxacin included heavy or persistent carriers (Table 
1). Consequently, as shown in Figure 5, the proportion 
of patients with failed eradication in the placebo arm 
Minocycline Coumermycin-A1
Sch29482
Cephalexin
Ciprofloxacin
Azythromycin
Spectinomycin
Ceftriaxone
SulphadimidineSulphadiazine
Minocycline 
+ Rifampin
Ampicillin
Penicillin
Placebo
Rifampin
1
1
1
1
1
111
1
1
1
1
1
1
1
1
2
2 2
2
3
3
7
Figure 1  Network of comparisons antibiotics for 
preventing meningococcal infections. The lines that 
connect antibiotics refer the direct comparison of two 
antibiotics. The number beside a line is the number of 
trials that directly compared the two antibiotics lined by 
the line.
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Figure 2  Funnel plot - estimated effects (log odds ratio) of antibiotics 
in placebo-controlled studies. Funnel plot asymmetry was not statistically 
significant (Harbord’s test for small study effects P = 0.600).
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was much higher in trials of ciprofloxacin than that in 
  Ref. Antibiotics Country and 
population
Carrier status Serogroups 
and 
susceptibility
Study design Sequence 
generation
Allocation 
concealment 
Blinding
  Blakebrough et al[14] Rifampin: 4 × 75 mg for 0-2 
yr, 4 × 150 mg for 2-4 yr, 4 × 
300 mg for 5-14 yr, 4 × 600 
mg for > 15 yr (bid, 2 d)
Sulphadimidine: 4 × 250 mg 
for 0-4 yr, 4 × 500 mg for 5-14 
yr, 4 × 1 g for > 15 yr (bid, 2 
d)
Nigeria 
Household 
contacts 
Any carriers Group A
Susceptibility 
tested
Cluster 
quasi-RCT 
Inadequate Inadequate Open
  Borgoño et al[15] Rifampin: 2 × 10 mg/kg 
Placebo 
Chile 
Children
Any carriers Group 
unknown
Susceptibility 
not tested
 RCT Unclear  Unclear Double-blind
  Cuevas et al[16] Rifampin: 4 × 600 mg for > 
18 yr, 4 × 20 mg/kg for 2-18 
yr (bid, 2 d) 
Ciprofloxacin: 1 × 750 mg for 
> 18 yr, 1 × 15 mg/kg for 2-18 
yr
Malawi 
Household 
contacts
Any carriers Group A: 51% 
(unknown 
49%) 
Susceptibility 
tested
Cluster RCT Unclear  Unclear Open
  Deal et al[17] Rifampin: 4 × 600 mg (4 d) 
Placebo 
United States 
Healthy 
students
Heavy/ 
Persistent 
(3 positive 
cultures) 
Group B 
Susceptibility 
tested
 RCT Adequate Adequate Double-blind
  Deal et al[18] Cephalexin: 12 × 500 mg (tid, 
4 d)
Placebo 
United States 
Students 
Persistent 
(3 positive 
cultures) 
Group B 
Susceptibility 
tested 
RCT Adequate Adequate Double-blind 
  Deviatkina et al[19] Rifampin: 4 × 300 mg (4 d) 
Placebo 
Russia 
Unclear 
Unknown Group 
unknown
Susceptibility 
tested
 RCT Unclear Unclear Open 
  Devine et al[20] Rifampin: 4 × 600 mg (4 d) 
Placebo 
United States 
Army recruits
Any carriers Group Y: 79%
Susceptibility 
tested
 RCT Adequate Unclear Double-blind 
  Devine et al[21] Coumermycin A1: 14 × 50 
mg (bid, 7 d)
Placebo 
United States 
Army recruits
Any carriers Group 
unknown 
Susceptibility 
tested
RCT Adequate Unclear Double-blind 
  Devine et al[22] Minocycline: 1 × 200 mg + 9 
× 100 mg (bid, 5 d)
Placebo 
United States 
Army recruits 
Any carriers Group Y: 63% 
Susceptibility 
tested 
RCT Adequate Unclear Double-blind
  Devine et al[22] Minocycline: 4 × 200 mg (bid, 
2 d) 
No antibiotic 
United States 
Army recruits
Any carriers Group Y: 
Most 
Susceptibility 
tested 
RCT Adequate Unclear Open 
  Dowd et al[23] Ampicillin: 30 × 500 mg (tid, 
10 d)
Penicillin: 30 × 462 mg (tid, 
10 d)
Placebo 
United States
Amy recruits 
Any carriers Group B and 
sulfadiazine-
resistant 
RCT Unclear Unclear Double-blind 
  Dworzack et al[24] Ciprofloxacin: 1 × 750 mg 
Placebo
United States 
Young adults
Persistent 
(3 positive 
cultures)
Group B: 41%, 
Z: 33% 
Susceptibility 
tested 
 RCT Unclear  Unclear Double-blind
  Girgis et al[25] Rifampin: 4 × 600 mg (bid, 2 
d) 
Azithromycin: 1 × 500 mg 
Egypt 
Nursing 
students 
Any carriers Group A: 37%; 
B: 33%
Susceptibility 
tested 
RCT Adequate Unclear Open 
  Guttler et al[26] Rifampin: 5 × 600 mg (5 d)
Minocycline 10 × 100 mg 
(bid, 5 d)
Ampicillin 10 × 500 mg (bid, 
5 d) 
Placebo
United States 
Army recruits
Any carriers Group B or 
C: 31% (non- 
groupable 
67%) 
Susceptibility 
tested 
 Cluster RCT Adequate Unclear Open 
  Judson et al[27] Ceftriaxone: im 1 × 125 mg
Spectinomycin: im 1 × 2 g 
United States 
Patients with 
gonorrhoea 
Any carriers Group 
unknown 
Susceptibility 
tested 
RCT Unclear Unclear Outcome 
assessment 
blinded
Table 1  Main characteristics of studies included in network meta-analysis 
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trials of rifampin (83% vs 55%). If the absolute results 
of antibiotic interventions were not influenced by the 
proportion of participants with persistent carriage, trials 
that included persistent carriers will show greater relative 
treatment effects purely because of the high failure rates 
in the placebo group (Figure 5). Therefore, imbalanced 
distribution of types of carriers across different sets 
of trials may invalid the similarity assumption in the 
network meta-analysis, which raises a question whether 
the indirect comparison is valid in this case. 
In addition, the use of ciprofloxacin in the direct 
comparison trials[16,29] was different from its use in the 
placebo-controlled trials of ciprofloxacin[24,31,33]. A single 
dose of ciprofloxacin was compared with multiple doses 
of rifampin in the two direct comparison trials, while 
two of the three placebo-controlled trials of ciprofloxacin 
compared placebo and multiple doses of ciprofloxacin 
(Table 1). Therefore, the effect of ciprofloxacin (with 
multiple doses) in the placebo-controlled trials may be 
enhanced as compared to the single dose in the two 
direct comparison trials. The eradication failure in the 
ciprofloxacin arm at one week was 10.5% in the direct 
comparison trials, as compare with only 3.0% in the 
placebo-controlled trials (Figure 5). The different doses 
of ciprofloxacin used in the direct comparison trials and 
in the placebo-controlled trials also contributed to the 
significant inconsistency observed. 
DISCUSSION
According to this network meta-analysis, a range of 
  Kaiser et al[28] Rifampin: 4 × 600 mg for 
weight ≥ 66 lb, or 4 × 300 
mg for weight < 66 lb (4 d) 
Placebo 
United States 
Household 
contacts
Any carriers Group C: 35%
Susceptibility 
tested
 RCT Adequate Unclear Open 
  Kaya et al[29] Rifampin: 4 × 600 mg (bid, 2 
d) 
Ciprofloxacin: 1 × 750 mg
Turkey 
Healthy 
adults
Any carriers Group 
unknown 
Susceptibility 
not tested
 Quasi RCT Inadequate  Inadequate Open
  Munford et al[30] Rifampin: 4 × 600 mg (bid, 2 
d)
Minocycline: 1 × 200 mg + 5 
× 100 mg (bid, 3 d)
Rifampin + Minocycline: as 
above
Sulphadiazine: 4 × 1 g (bid, 2 
d) 
Brazil 
Household 
contacts 
Any carriers Group C: 
Most 
Susceptibility 
tested 
Cluster 
quasi-RCT 
Inadequate Inadequate Open 
  Pugsley et al[32] Sch29482: 16 × 250 mg (every 
6 h for 4 d) 
Placebo 
United States Persistent 
carriers (2 
positive 
cultures) 
Group Z: 36%; 
B: 24%
RCT Adequate Unclear Double-blind 
  Pugsley et al[31] Ciprofloxacin: 10 × 500 mg 
(bid, 5 d) 
Placebo
Young men 
United States 
Persistent 
(2 positive 
cultures)
Susceptibility 
tested 
Group B: 79%
 RCT Adequate  Unclear Double-blind
  Renkonen et al[33] Ciprofloxacin: 4 × 250 mg 
(bid, 2 d) 
Placebo
Young adults
Finland 
Heavy (> 100 
colonies per 
plate) 
Susceptibility 
tested 
Group B: 45% 
 RCT Adequate  Adequate Double-blind
  Schwartz et al[34] Rifampin: 4 × 600 mg or 4 × 
10 mg/kg (bid, 2 d)
Army recruits
Saudi Arabia 
Any carriers Susceptibility 
tested 
Group A 
Cluster RCT Unclear Unclear Open 
  Simmons et al[35] Ceftriaxone: im 1 × 250 mg 
(or 125 mg for < 15 yr) 
Rifampin: 4 × 600 mg for 
adults, 4 × 5 mg/kg for 
children < 1 mo, and 4 × 10 
mg for children > 1 mo (bid, 
2 d)
Ceftriaxone: im 1 × 250 mg, 
or 1 × 125 mg for < 12 yr
Household 
contacts 
New Zealand 
Household 
contacts 
Any carriers Susceptibility 
tested 
Group B: 53% 
Susceptibility 
tested
RCT Unclear Unclear Open 
im: Intramuscular; bid: Twice a day; tid: Three times a day; RCT: Randomized controlled trials.
Inconsistency (logROR)
-10                      0                      10
Rifampin vs  ciprofloxacin
Rifampin vs  minocycline
Rifampin vs  ampicillin
Minocycline vs  ampicillin
Figure 3  Inconsistencies (and 95%CIs) between direct and indirect esti-
mates for comparisons with closed loops. logROR: 0 indicates no difference 
between the direct and indirect estimates.
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antibiotic regimens are effective for preventing meningo-
coccal infections in carriers. The simultaneous analysis of 
all randomised controlled trials that could be connected 
in a coherent network provided results that were 
not available from the conventional pair-wise meta-
analysis[43]. The network meta-analysis revealed that 
a combination of rifampin and minocycline seems the 
most efficacious, and ceftriaxone is also likely to be more 
effective than the antibiotics (ciprofloxacin or rifampin) 
recommended by the current guidelines[4-6]. The network 
  Trial Regimen n Failure to 
eradicate
  Guttler et al[26] Placebo   18 (146)   8 (65)
Rifampin   18 (147)   2 (13) 
Minocycline   18 (147)   1 (12) 
Ampicillin   18 (147)   3 (22)
  Munford et al[30] Rifampin 65 (67) 6 (6) 
Sulphadiazine 79 (82) 37 (38) 
Minocycline 56 (58) 6 (6) 
Rifampin + Minocycline 59 (61) 0 (0) 
  Schwartz et al[34] Rifampin 34 (36) 9 (9) 
Ceftriaxone 65 (68) 2 (2) 
  Dowd et al[23] Placebo    47     26
Penicillin    20       9
Ampicillin    26       8
  Borgoño et al[15] Placebo  110     71
Rifampin  118     10
  Deal et al[17] Placebo    15     13
Rifampin    15       2
  Deviatkina et al[19] Placebo    43     10
Rifampin    46       3
  Devine et al[20] Placebo    28     25
Rifampin    38       7
  Kaiser et al[28] Placebo      6       6
Rifampin    13       1
  Dworzack et al[24] Placebo    22     20
Ciprofloxacin    24       1
  Pugsley et al[31] Placebo    21     14
Ciprofloxacin    21       0
  Renkonen et al[33] Placebo    53     46
Ciprofloxacin    56       2
  Deal et al[18] Placebo    15     14
Cephalexin    15     11
  Devine et al[22] Placebo    48     42
Minocycline    41     14
  Devine et al[22] Placebo    29     27
Minocycline    53     16
  Devine et al[21] Placebo    39     28
Coumermycin A1    33     31
  Pugsley et al[32] Placebo    29     26
Sch29482    29     23
  Cuevas et al[16] Rifampin    84 (88)       3 (3) 
Ciprofloxacin    75 (79)       9 (9) 
  Kaya et al[29] Rifampin    25       1
Ciprofloxacin    26       2
  Girgis et al[25] Rifampin    59       3
Azythromycin    60       4
  Simmons et al[35] Rifampin    82       4
Ceftriaxone  100       3
  Blakebrough et al[14] Rifampin    46 (48)     11 (11) 
Sulphadimidine    33 (34)     33 (34) 
  Judson et al[27] Ceftriaxone    29       0
Spectinomycin      9       8
Table 2  Antibiotics compared and data from the included 
trials for network meta-analysis
For cluster trials, ICC = 0.05 was assumed for estimating effective sample 
sizes, and original sample size and events in cluster trials are shown in 
brackets. 
Odds ratio (95%CI)
0.001               0.1                  10
Rifampin vs  ciprofloxacin
Cueveas 1995
Kaya 1997
Direct comparison
Indirect comoarrison
Rifampin vs  placebo
Borgono 1981
Deal 1969a
Devlatklna 1978
Devlne 1970b
Guttler 1971
Kalser 1974
Plooled
Ciprofloxacin vs  placebo
Dworzack 1988
Pugsley 1987
Renkonen 1987
Pooled
Figure 4  Rifampin vs ciprofloxacin for preventing meningococcal 
infections. The outcome is the failure to eradicate at 1 wk. Pooled direct and 
indirect estimates were the results of mixed treatment comparison, and other 
results were from DerSimonian-Laird meta-analyses.
Ciprofloxacin
Rifampin
Ciprofloxacin
Placebo
Rifampin
Placebo
0%             25%            50%            75%          100%
Failure to eradicate
10.5%
3.5%
3.0%
83.3%
9.6%
54.6%
Figure 5  Proportions of failure to eradicate in individual arms of trials for 
the direct and indirect comparison of rifampin and ciprofloxacin. 
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Methodological implications 
One of the main advantages of network meta-analysis is 
pooling of all connected trials into a coherent network of 
evidence. However, a study found that the inconsistency 
between direct and indirect evidence may be more 
prevalent than previously observed[45], and it has 
been generally accepted that causes of inconsistency 
in network meta-analysis should be carefully investi-
gated[36,46-48]. In the current study, statistical meta-
regression analyses found that the type of carriers 
(persistent vs any, and household contacts vs other) 
may be a cause of heterogeneity in the network meta-
analysis. However, the usefulness of statistical methods 
for investigating causes of inconsistency is often limited 
because of the small number of trials, inadequate 
reporting of relevant variables, and modelling complexity. 
The narrative investigation of causes of inconsis-
tency is difficult for a complex network. The existence 
of evidence inconsistencies in a network meta-analysis 
does not mean that the whole network is inconsis-
tent[46]. Therefore, we focused on the investigation of 
statistically significant inconsistencies. To further simplify 
the narrative investigation, a sub-network of trials was 
formed after excluding those that are only remotely 
connected to the target comparison. 
We demonstrated that focused examination of 
characteristics of trial participants and interventions 
evaluated may reveal the clinically meaningful causes 
of inconsistency in network meta-analysis. The detailed 
examination of trial participants and interventions 
evaluated is similar to the investigation of heterogeneity 
in conventional pair-wise meta-analysis. Although the 
type of carriers (persistent vs any) can be identified 
by both statistical covariate analysis and narrative 
investigation, the difference in doses of ciprofloxacin 
as a possible cause of inconsistency could not be 
investigated by the statistical models we used. How-
ever, the narrative investigation mainly relies on subjec-
tive judgement, is restricted by available data from 
published studies, and a good understanding of the 
topic is required. 
Study limitations
In order to include as many studies as possible in the 
trial network, we focused on eradication failure and did 
not consider other important outcomes such as adverse 
effects and new cases of meningococcal disease. 
Included studies were mostly conducted in 1970s or 
1980s, and the most recent study was published in 
2000[35]. Therefore, it is a question about whether the 
results of previous randomised controlled trials are 
applicable to the present. Although we included only 
randomised controlled trials, the quality of the included 
trials was poor, with considerable risk of bias. According 
to the results of meta-regression analyses (Table 4), 
the treatment effects were not significantly associated 
with whether a trial was cluster or quasi randomised, 
whether the sequence generation was inadequate, and 
whether it was blinded. In addition, publication and 
outcome reporting bias was possible. Funnel plot using 
data from placebo-controlled trials indicated that there 
was no statistically significant small-study effect. 
Conclusion
The network meta-analysis confirms that a range 
of prophylactic antibiotic regimens are effective for 
eradicating meningococcal carriages, and treatment 
choice will depend on the individual priorities of the 
patients and physicians. In clinical situations where 
complete eradication is considered to be of the utmost 
importance, a combination of rifampin and minocycline 
seems to offer the highest likelihood of success. 
Ceftriaxone as a single intramuscular injection is also 
likely to be more effective as compared with the two 
  Covariate Regression coefficient, b (95%CI) Between-study variation (τ)
  Persistent carrier (1) vs any carriers (0) -2.904 (-4.695 to -1.186) 0.434
  Household (1) vs other (0) -6.178 (-16.79 to -0.069) 0.975
  Cluster/quasi RCT (1) vs RCT (0) 0.405 (-2.235 to 2.881) 1.082
  Sequence generation inadequate (1) vs adequate (0) 0.461 (-1.301 to 2.014) 1.025
  Open design (1) vs blinded (0) 0.055 (-1.877 to 1.662) 1.087
Table 4  Results of covariate effects in network meta-analysis: Regression coefficient and between study variation
MTC estimate Direct estimate Indirect estimate
  Comparison No. of trials OR (95%CrI) No. of trials OR (95%CrI) No. of trials OR (95%CrI)
  Rifampin vs ciprofloxacin 23 0.52 (0.13, 1.89) 2   2.51 (0.36, 15.64) 21 0.09 (0.017, 0.40)
  Rifampin vs minocycline 23 1.55 (0.40, 6.07) 2 0.85 (0.11, 5.59) 21 2.27 (0.28, 19.89)
  Rifampin vs ampicillin 23 6.94 (1.21, 37.53) 1   1.62 (0.09, 29.82) 20 12.23 (1.04, 146.9)
  Minocycline vs ampicillin 23 4.52 (0.67, 28.30) 1   3.46 (0.16, 91.10) 20 6.50 (0.41, 93.6)
Table 5  Results of different methods for four comparisons that provided sufficient trials for both direct and indirect comparisons 
 b > 0 indicating that treatment effect is smaller when the covariate exists. RCT: Randomized controlled trial. 
MTC: Mixed treatment comparison based on all data in the network of trials. 
Abdelhamid AS et al . Chemoprophylaxis and meningococcal infections
86 August 26, 2016|Volume 4|Issue 4|WJMA|www.wjgnet.com
recommended antibiotics (ciprofloxacin or rifampin) by 
the current guidelines. Variation in the type of carriage 
and dosage regimens of ciprofloxacin may account for 
the observed inconsistency in the direct and indirect 
comparisons of rifampin and ciprofloxacin. Detailed 
examination of characteristics of relevant studies should 
be conducted for investigating causes of inconsistency 
in network meta-analysis. 
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